It references the article "Price of Drugs for Chronic Myeloid Leukemia (CML): Reflection of the Unsustainable Cancer Drug Prices: Perspective of CML Experts" in the April 25, 2013 issue of "Blood." It notes that experts in CML commented on the unsustainable prices of tyrosine kinase inhibitor...
Dasatinib (Sprycel®) is an orally administered small molecule inhibitor of multiple tyrosine kinases, including BCR-ABL and SRC family kinases, which is indicated for the treatment of adults with newly diagnosed chronic-phase chronic myeloid leukaemia (CML), CML (chronic-, accelerated-or blast-ph...
However, these agents do not have the long-term track record of imatinib. This article summarizes the published data and reviews the rationale in choosing the appropriate TKI for first-line treatment of CML in the chronic phase. 展开 关键词: BCR-ABL CML dasatinib imatinib nilotinib ...
Part 1 of a 2 Part Article: A Comprehensive Review of Imatinib Mesylate (Gleevec) for Dermatological Diseases Imatinib mesylate (Gleevec, also known as STI-571), is an approved oral treatment for patients with chronic myeloid leukemia (CML). It blocks the activity of Abelson cytoplasmic tyrosine...
have been used for decades to combat cancer. However, the emergence of novel fields of cancer research has led to the exploration of innovative treatment approaches focused on immunotherapy, epigenetic therapy, targeted therapy, multi-omics, and also multi-target therapy. The hypothesis was based on...
Research Network (BIRN) was developed in this mode. Funded by the National Institutes of Health, BIRN is a “geographically distributed virtual community of shared resources offering tremendous potential to advance the diagnosis and treatment of disease” (Biomedical Informatics Research Network, 2007)....
Finally, the targeted drugs for ONFH were identified through the Drug-Gene Interaction Database (DGIdb) and cross-validated by integrated literature mining. Our study figured out the drug-gene-disease correlation to generate new insights into the prevention and treatment of ONFH. Table 1 Detailed ...
Active transport of imatinib into and out of cells: implications for drug resistance. Imatinib is a tyrosine kinase inhibitor that is effective in the treatment of chronic myeloid leukemia (CML). Not all patients achieve cytogenetic response... J Thomas,L Wang,RE Clark,... - 《Blood》 被引...
Methods Study Design This study was conducted to quantify the reported global incomes from the sales of individual drugs approved by the US Food and Drug Administration (FDA) between 1989 and 2017 for the treatment and prevention of hematological cancers, solid tumors, and related conditions such ...
Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia Introduction: Chronic myeloid leukemia (CML) is a disease in which outstanding discoveries and achievements have been made over the past two decades. The u... H Ghanem,H Kantarjian,J Cortes,... - 《Bul...